On Tuesday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) opened lower -1.93% from the last session, before settling in for the closing price of $11.93. Price fluctuations for KALV have ranged from $7.30 to $15.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.06% over the last five years. Company’s average yearly earnings per share was noted -3.28% at the time writing. With a float of $38.49 million, this company’s outstanding shares have now reached $49.49 million.
The firm has a total of 150 workers. Let’s measure their productivity. In terms of profitability, gross margin is 63.27%, operating margin of -15043.2%, and the pretax margin is -14230.76%.
KalVista Pharmaceuticals Inc (KALV) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of KalVista Pharmaceuticals Inc is 22.58%, while institutional ownership is 88.37%. The most recent insider transaction that took place on Jun 09 ’25, was worth 103,950. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,169 shares at a rate of $14.50, taking the stock ownership to the 315,074 shares. Before that another transaction happened on May 23 ’25, when Company’s CHIEF MEDICAL OFFICER sold 2,146 for $11.31, making the entire transaction worth $24,272. This insider now owns 113,026 shares in total.
KalVista Pharmaceuticals Inc (KALV) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.36% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Check out the current performance indicators for KalVista Pharmaceuticals Inc (KALV). In the past quarter, the stock posted a quick ratio of 10.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.98 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Analysing the last 5-days average volume posted by the [KalVista Pharmaceuticals Inc, KALV], we can find that recorded value of 1.99 million was better than the volume posted last year of 0.6 million. As of the previous 9 days, the stock’s Stochastic %D was 16.27%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 48.87%, which indicates a significant increase from 37.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.03% in the past 14 days, which was lower than the 54.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.49, while its 200-day Moving Average is $10.92. Now, the first resistance to watch is $12.94. This is followed by the second major resistance level at $14.19. The third major resistance level sits at $15.74. If the price goes on to break the first support level at $10.14, it is likely to go to the next support level at $8.59. Now, if the price goes above the second support level, the third support stands at $7.34.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
There are currently 49,716K shares outstanding in the company with a market cap of 581.68 million. Presently, the company’s annual sales total 0 K according to its annual income of -126,640 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -48,510 K.
